 |
|
Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy
A Losartan Intervention For Endpoint Reduction (LIFE) Substudy
Sverre E. Kjeldsen, MD;
Björn Dahlöf, MD;
Richard B. Devereux, MD;
Stevo Julius, MD;
Peter Aurup, MD;
Jonathan Edelman, MD;
Gareth Beevers, MD;
Ulf de Faire, MD;
Frej Fyhrquist, MD;
Hans Ibsen, MD;
Krister Kristianson, MD;
Ole Lederballe-Pedersen, MD;
Lars H. Lindholm, MD;
Markku S. Nieminen, MD;
Per Omvik, MD;
Suzanne Oparil, MD;
Steven Snapinn, PhD;
Hans Wedel, PhD;
for the LIFE Study Group
JAMA. 2002;288:1491-1498.
Context Drug intervention in placebo-controlled trials has been beneficial in isolated systolic hypertension.
Objective To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH).
Design Double-blind, randomized, parallel-group study conducted in 1995-2001.
Setting and Participants A total of 1326 men and women aged 55 through 80 years (mean, 70 years) with systolic blood pressure of 160 to 200 mm Hg and diastolic blood pressure of less than 90 mm Hg (mean, 174/83 mm Hg) and ECG-LVH, recruited from 945 outpatient settings in the Nordic countries, the United Kingdom, and the United States.
Interventions Patients were randomly assigned to receive once-daily losartan (n = 660) or atenolol (n = 666) with hydrochlorothiazide as the second agent in both arms, for a mean of 4.7 years.
Main Outcome Measure Composite end point of cardiovascular death, stroke, or myocardial infarction.
Results Blood pressure was reduced by 28/9 and 28/9 mm Hg in the losartan and atenolol arms. The main outcome was reduced by 25% with losartan compared with atenolol, 25.1 vs 35.4 events per 1000 patient-years (relative risk [RR], 0.75; 95% confidence interval [CI], 0.56-1.01; P = .06, adjusted for risk and degree of ECG-LVH; unadjusted RR, 0.71; 95% CI, 0.53-0.95; P = .02). Patients receiving losartan had reductions in the following without a difference in the incidence of myocardial infarction: cardiovascular mortality (8.7 vs 16.9 events per 1000 patient-years; RR, 0.54; 95% CI, 0.34-0.87; P = .01), nonfatal and fatal stroke (10.6 vs 18.9 events per 1000 patient-years; RR, 0.60; 95% CI, 0.38-0.92; P = .02), new-onset diabetes (12.6 vs 20.1 events per 1000 patient-years; RR, 0.62; 95% CI, 0.40-0.97; P = .04), and total mortality (21.2 vs 30.2 events per 1000 patient-years; RR, 0.72; 95% CI, 0.53-1.00; P = .046). Losartan decreased ECG-LVH more than atenolol (P<.001) and was better tolerated.
Conclusion These data suggest that losartan is superior to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH.
Author Affiliations: Department of Internal Medicine, Division of Hypertension, University of Michigan, Ann Arbor (Drs Kjeldsen and Julius); Department of Cardiology, Ullevaal University Hospital, Oslo, Norway (Dr Kjeldsen); Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden (Dr Dahlöf); Division of Cardiology, Cornell Medical Center, New York, NY (Dr Devereux); Merck & Co Inc, Whitehouse Station, NJ (Drs Aurup, Edelman, and Snapinn); City Hospital, Birmingham, England (Dr Beevers); Department of Medicine, Division of Cardiovascular Medicine, Karolinska University Hospital, Stockholm, Sweden (Dr de Faire); Department of Medicine (Dr Fyhrquist) and Division of Cardiology (Dr Nieminen), Helsinki University Central Hospital, Finland; Department of Internal Medicine, Glostrup University Hospital, Denmark (Dr Ibsen); Merck Research Laboratories Scandinavia, Stockholm, Sweden (Dr Kristianson); Department of Internal Medicine, Viborg Hospital, Denmark (Dr Lederballe-Pedersen); Umeå University, Sweden (Dr Lindholm); Division of Cardiology, Haukeland University Hospital, Bergen, Norway (Dr Omvik); Division of Cardiovascular Disease, University of Alabama, Birmingham (Dr Oparil); and the Nordic School of Public Health, Göteborg, Sweden (Dr Wedel).
RELATED LETTERS
Losartan vs Atenolol in Prevention of Stroke and Cardiovascular Disease
Albert Fournier, Roxana Oprisiu, Michel Andrejak, Leonardo Fernandez, and Jean Michel Achard
JAMA. 2003;289(6):700.
EXTRACT
| FULL TEXT
Losartan vs Atenolol in Prevention of Stroke and Cardiovascular Disease
Franz H. Messerli, Ehud Grossman, and Albert Fournier
JAMA. 2003;289(6):700-701.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT
Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look
Reudelhuber et al.
Hypertension 2007;49:1196-1201.
FULL TEXT
Increased Insulin-Stimulated Expression of Arterial Angiotensinogen and Angiotensin Type 1 Receptor in Patients With Type 2 Diabetes Mellitus and Atheroma
Hodroj et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:525-531.
ABSTRACT
| FULL TEXT
Angiotensin II-induced NADPH Oxidase Activation Impairs Insulin Signaling in Skeletal Muscle Cells
Wei et al.
J. Biol. Chem. 2006;281:35137-35146.
ABSTRACT
| FULL TEXT
Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.
Daneshtalab et al.
J Clin Pharmacol 2006;46:1344-1355.
ABSTRACT
| FULL TEXT
Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System.
Volpe et al.
J. Am. Soc. Nephrol. 2006;17:S36-S43.
ABSTRACT
| FULL TEXT
Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk: A LIFE Substudy
Franklin et al.
Hypertension 2005;46:492-499.
ABSTRACT
| FULL TEXT
Control of Hypertension in Adults With Chronic Kidney Disease in the United States
Peralta et al.
Hypertension 2005;45:1119-1124.
ABSTRACT
| FULL TEXT
Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy
Fyhrquist et al.
Hypertension 2005;45:580-585.
ABSTRACT
| FULL TEXT
Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study
Kizer et al.
Hypertension 2005;45:46-52.
ABSTRACT
| FULL TEXT
Management of Hypertension in the Very Elderly Patient
Elliott
Hypertension 2004;44:800-804.
ABSTRACT
| FULL TEXT
Left Ventricular Hypertrophy: The Next Treatable, Silent Killer?
Gardin and Lauer
JAMA 2004;292:2396-2398.
FULL TEXT
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE)
Papademetriou et al.
J Am Coll Cardiol 2004;44:1175-1180.
ABSTRACT
| FULL TEXT
Systolic Hypertension in Older Persons
Chaudhry et al.
JAMA 2004;292:1074-1080.
ABSTRACT
| FULL TEXT
Should Angiotensin II Receptor Blockers and Statins Be Combined?
Nickenig
Circulation 2004;110:1013-1020.
FULL TEXT
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman et al.
Arch Intern Med 2004;164:1490-1500.
ABSTRACT
| FULL TEXT
Hypertensive Therapy: Part II
Franco et al.
Circulation 2004;109:3081-3088.
FULL TEXT
The Clinician as Investigator: Participating in Clinical Trials in the Practice Setting: Appendix 1: Fundamentals of Study Design
Lader et al.
Circulation 2004;109:e302-e304.
FULL TEXT
Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials
Fournier et al.
J Am Coll Cardiol 2004;43:1343-1347.
ABSTRACT
| FULL TEXT
Hypertrophy of the Heart: A New Therapeutic Target?
Frey et al.
Circulation 2004;109:1580-1589.
ABSTRACT
| FULL TEXT
Effects of Losartan and Simvastatin on Monocyte-Derived Microparticles in Hypertensive Patients With and Without Type 2 Diabetes Mellitus
Nomura et al.
CLIN APPL THROMB HEMOST 2004;10:133-141.
ABSTRACT
Current and future concepts in stroke prevention
O'Rourke et al.
CMAJ 2004;170:1123-1133.
ABSTRACT
| FULL TEXT
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study
Julius et al.
J Am Coll Cardiol 2004;43:1047-1055.
ABSTRACT
| FULL TEXT
Raloxifene Prevents Cardiac Hypertrophy and Dysfunction in Pressure-Overloaded Mice
Ogita et al.
Hypertension 2004;43:237-242.
ABSTRACT
| FULL TEXT
Vascular Protection of ACE Inhibitors--Reply
Jacoby and Rader
Arch Intern Med 2003;163:2792-2793.
FULL TEXT
Pathogenesis of Hypertension
Oparil et al.
ANN INTERN MED 2003;139:761-776.
FULL TEXT
Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial
Devereux et al.
ANN INTERN MED 2003;139:169-177.
ABSTRACT
| FULL TEXT
Cerebral involvement in hypertensive cardiovascular disease
Coca
Eur Heart J Suppl 2003;5:F19-F25.
ABSTRACT
Review: Implications from hypertension outcome trials for the management of patients with hypertension and diabetes
Brown
British Journal of Diabetes & Vascular Disease 2003;3:245-251.
ABSTRACT
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
Chobanian et al.
JAMA 2003;289:2560-2571.
ABSTRACT
| FULL TEXT
The LIFE study: the straw that should break the camel's back
Messerli
Eur Heart J 2003;24:487-489.
FULL TEXT
Losartan was more effective than atenolol for isolated systolic hypertension and left ventricular hypertrophy
Rembold
Evid. Based Med. 2003;8:43-43.
FULL TEXT
Losartan vs Atenolol in Prevention of Stroke and Cardiovascular Disease
Fournier et al.
JAMA 2003;289:700-700.
FULL TEXT
Losartan vs Atenolol in Prevention of Stroke and Cardiovascular Disease
Messerli et al.
JAMA 2003;289:700-701.
FULL TEXT
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT
JournalScan
Malik
Heart 2002;88:671-672.
FULL TEXT
Losartan vs. Atenolol for Isolated Systolic Hypertension
JWatch General 2002;2002:1-1.
FULL TEXT
|
